Ponatinib Hydrochloride
Price | $1 |
Package | 1KG |
Min. Order: | 1KG |
Supply Ability: | 1KG;5KG 10KG; 100KG |
Update Time: | 2019-09-03 |
Product Details
Product Name: Ponatinib Hydrochloride | CAS No.: 1114544-31-8 |
Min. Order: 1KG | Purity: 95.0-99.8% |
Supply Ability: 1KG;5KG 10KG; 100KG | Release date: 2019/09/03 |
Product number: Crystal-liu |
▼
▲
Product Name:
Ponatinib Hydrochloride
Synonyms:
AP24534 Mono-hydrochloride;Ponatinib Mono-hydrochloride;3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide hydrochloride;Ponatinib hydrochloride;Ponatinib-HCl;AP24534-HCl;1114544-31-8
CAS:
1114544-31-8
MF:
C29H28ClF3N6O
MW:
569.02
EINECS:
1592732-453-0
Product Categories:
Mol File:
1114544-31-8.mol
▼
▲
Ponatinib Hydrochloride Chemical Properties
▼
▲
▼
▲
Safety Information
▼
▲
▼
▲
MSDS Information
▼
▲
Ponatinib Hydrochloride Usage And Synthesis
▼
▲
Description
In December 2012, the US FDA approved ponatinib (also referred to as AP 24534) for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronicmyeloid leukemia (CML). Ponatinib is a pan-Bcr–Abl TKI that blocks both the native (IC50=0.4 nM) and Bcr– AblT315I mutated kinases (IC50=2.0 nM) in addition to othermutated kinases in CML patients. In the Ba/F3 cell proliferation assay, ponatinib inhibits ABL and the T315I Abl mutant with IC50s of 1.2 and 8.8 nM, respectively. Ponatinib was identified by a structure-based drug design approach. Ponatinib binds to the kinase domain in a DFG-out conformation; the ethynyl moiety helps the inhibitor evade the mutant gatekeeper isoleucine residue at position 315. In addition to Abl and the T315I mutant of Abl, ponatinib inhibits VEGFR, PDGFR, FGFR, SRC, KIT, RET, TIE2, FLT3, and EPH receptors at concentrations ranging from0.1 to 20 nM.
Originator
Ariad (United States)
Brand name
Iclusig
Company Profile Introduction
Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals.
Mainly deals in the sales of:
Pharmaceutical intermediates
OLED intermediates:
Pharmaceutical intermediates;
OLED intermediates;
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-07-24 | |
$0.00/1g |
Beijing Yibai Biotechnology Co., Ltd
|
2019-08-16 | ||
$50.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-15 | |
$678.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
$0.00/10mg |
VIP1Y
|
ShenZhen H&D Pharmaceutical Technology Co., LTD
|
2024-08-08 |
- Since: 2014-12-17
- Address: No.967,15th Floor,Unit 7, Building 1, No.70 of DianChang Road, High-tech Development Zone, Zhengzho
INQUIRY
楊俊青
sales@coreychem.com
sales@coreychem.com